Article
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2010
Togashi Yosuke, Masago Katsuhiro, Fukudo Masahide, Terada Tomohiro, Fujita Shiro, Irisa Kaoru, Sakamori Yuichi, Kim Young Hak, Mio Tadashi, Inui Ken-ichi, Mishima Michiaki
Abstract excerpt
BACKGROUND: Although there have been several reports in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) were improved by erlotinib, cerebrospinal fluid (CSF) penetration of erlotinib in such patients has not been reported. We investigated CSF concentrations of erlotinib and its active metabolite OSI-420. METHOD: We administered 150 mg erlotinib daily to four patients with NSCLC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.